1. 日本中性子捕捉療法学会 著: BNCT基礎から臨床応用まで ‐BNCTを用いて治療にかかわる人のためのテキスト‐, 大阪公立大学共同出版会, 大阪, 2018
2. Joensuu H, Kankaanranta L, Seppälä T et al. Boron neutron capture therapy of brain tumors: Clinical trials at the Finnish facility using boronophenylalanine. J Neurooncol 2003;62:123–34.
3. Kankaanranta L, Seppälä T, Koivunoro H et al. L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: A phase i study. Int J Radiat Oncol Biol Phys 2011;80:369–76.
4. Minohara S, Endo M, Kanai T et al. Estimating uncertainties of the geometrical range of particle radiotherapy during respiration. Int J Radiat Oncol Biol Phys 2003;56:121–5.
5. Ariyoshi Y, Miyatake S, Kimura Y et al. Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep 2007:861–6.
6. Kankaanranta L, Seppälä T, Koivunoro H et al. Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2007;69:475–82.
7. Aihara T, Morita N, Kamitani N et al. Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck. Int J Clin Oncol 2014;19:437–44.
8. Soloway AH, Hatanaka H, Davis MA. Penetration of Brain and Brain Tumor. V II. Tumor-Binding Sulfhydryl Boron Compounds. J Med Chem 1967;10:714–7.
9. Mishima Y, Honda C, Ichihashi M. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10b-compound. Lancet 1989;334:388–9.
10. Detta A, Cruickshank GS. L-Amino Acid Transporter-1 and Boronophenylalanine-Based Boron Neutron Capture Therapy of Human Brain Tumors. Cancer Res 2009;69:2126–32.
11. Soloway AH, Tjarks W, Barnum BA et al. The Chemistry of Neutron Capture Therapy. Chem Rev 1998;98:1515–62.
12. Ishiwata K, Ido T, Mejia AA et al. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-d,l-phenylalanine: A target compound for PET and boron neutron capture therapy. Int J Radiat Appl Instrumentation Part 1991;42:325–8.
13. Evangelista L, Jori G, Martini D et al. Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: A critical and clinical overview of theliterature. Appl Radiat Isot 2013;74:91–101.
14. Höckel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266–76.
15. Chapman JD. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother Oncol 1991;20:13–9.
16. Semenza GL, Agani F, Booth G et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997;51:553–5.
17. Pennacchietti S, Michieli P, Galluzzo M et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347–61.
18. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000;76:589–605.
19. Wada Y, Hirose K, Harada T et al. Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy. J Radiat Res 2018;59:122–8.
20. Masunaga SI, Tatebe H, Nishimura Y et al. Effect of oxygen pressure during incubation with a 10B-carrier on 10B uptake capacity of cultured p53 wild-type and mutated tumor cells: Dependency on p53 status of tumor cells and types of 10B-carriers. Int J Radiat Biol 2016;92:187–94.
21. Masunaga SI, Nagasawa H, Gotoh K et al. Evaluation of hypoxia-specific cytotoxic bioreductive agent-sodium borocaptate- 10B conjugates as 10B-carriers in boron neutron capture therapy. Radiat Med - Med Imaging Radiat Oncol 2006;24:98–107.
22. Luderer MJ, Muz B, de la Puente P et al. A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma. Pharm Res 2016;33:2530–9.
23. Hiramatsu R, Kawabata S, Tanaka H et al. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): Application for photodynamic therapy and boron neutron capture therapy. J Pharm Sci 2015;104:962–70.
24. Ichikawa G, Tsuchida K, Kiyanagi Y et al. Development of thermal neutron moderator for testing boron agents for Boron Neutron Capture Therapy (BNCT). J Instrum 2019;14:T06010–T06010.
25. Mucci A, Kunkiel J, Suzuki T et al. Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency. Stem Cell Reports 2016;7:292–305.
26. Nakamura M, Kyo S, Zhang B et al. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol 2010;41:1516–29.
27. Kim RK, Kaushik N, Suh Y et al. Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer. Oncotarget 2016;7:53430–42.
28. Brittenham GM. Iron-Chelating Therapy for Transfusional Iron Overload. Th e new engl J o f Med Clin 2011;364:146–56.
29. Wang X, Zhao R, Geranpayehvaghei M et al. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth. ACS Nano 2019;13:2176–89.
30. Yao Q, Liu Y, Selvaratnam B et al. Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering. J Control Release 2018;279:69–78.
31. Rajpurohit R, Koch CJ, Tao Z et al. Adaptation of chondrocytes to low oxygen tension: Relationship between hypoxia and cellular metabolism. J Cell Physiol 1996;168:424–32.
32. De Sousa CAF, Sodek L. Alanine metabolism and alanine aminotransferase activity in soybean (Glycine max) during hypoxia of the root system and subsequent return to normoxia. Environ Exp Bot 2003;50:1–8.
33. Harada H. Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistance. J Radiat Res 2016;57:i99–105.
34. Harada H, Inoue M, Itasaka S et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 2012;3, DOI: 10.1038/ncomms1786.
35. Friebe A, Müllershausen F, Smolenski A et al. YC-1 Potentiates Nitric Oxide- and Carbon Monoxide-Induced Cyclic GMP Effects in Human Platelets. Mol Pharmacol 1998;54:962–7.
36. Teng C. YC-1 , a nitric oxide-independent activator of soluble guanylate cyclase , inhibits platelet-rich thrombosis in mice. 1997:161–6.
37. Li SH, Shin DH, Chun Y-S et al. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1 . Mol Cancer Ther 2008;7:3729– 38.
38. Moon SY, Chang HW, Roh JL et al. Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral Oncol 2009;45:915–9.
39. Harada H, Itasaka S, Zhu Y et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 2009;100:747–57.
40. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer 1984;54:2441–9.
41. Troost EGC, Laverman P, Philippens MEP et al. Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008;35:1803–11.
42. Rischin D, Hicks RJ, Fisher R et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncolog. J Clin Oncol 2006;24:2098–104.
43. Wittig A, Sauerwein WA, Coderre JA. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res 2000;153:173–80.
44. Yoshimoto M, Honda N, Kurihara H et al. Non-invasive estimation of 10B-4-borono-L-phenylalanine-derived boron concentration in tumors by PET using 4-borono-2-18F-fluoro-phenylalanine. Cancer Sci 2018;109:1617–26.
45. Hayashi K, Anzai N. Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment. World J Gastrointest Oncol 2017;9:21–9.
論文の公開元へ
